Decibel Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Laurence Reid
Chief executive officer
US$1.2m
Total compensation
| CEO salary percentage | 44.5% |
| CEO tenure | 3.8yrs |
| CEO ownership | n/a |
| Management average tenure | 2.1yrs |
| Board average tenure | 2.4yrs |
Recent management updates
Recent updates
Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation
Aug 10
Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?
Feb 07Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial
Oct 17We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully
Sep 01Decibel Therapeutics: Gene Therapies For Hearing Loss
Jul 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$63m |
| Mar 31 2023 | n/a | n/a | -US$62m |
| Dec 31 2022 | US$1m | US$548k | -US$63m |
| Sep 30 2022 | n/a | n/a | -US$60m |
| Jun 30 2022 | n/a | n/a | -US$60m |
| Mar 31 2022 | n/a | n/a | -US$55m |
| Dec 31 2021 | US$801k | US$522k | -US$54m |
| Sep 30 2021 | n/a | n/a | US$576k |
| Jun 30 2021 | n/a | n/a | US$7m |
| Mar 31 2021 | n/a | n/a | US$8m |
| Dec 31 2020 | US$4m | US$574k | US$7m |
Compensation vs Market: Laurence's total compensation ($USD1.23M) is above average for companies of similar size in the US market ($USD738.70K).
Compensation vs Earnings: Laurence's compensation has increased whilst the company is unprofitable.
CEO
Laurence Reid (59 yo)
3.8yrs
Tenure
US$1,232,276
Compensation
Dr. Laurence E. Reid, Ph D., serves as President, Chief Executive Officer and until September 25, 2023 served as Director at Decibel Therapeutics, Inc. since January 2020 and served as its consultant since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & CEO | 3.8yrs | US$1.23m | no data | |
| Executive VP & Chief People Officer | 5.8yrs | US$618.23k | 0% $ 0 | |
| Executive VP & Chief Development Officer | 7.1yrs | US$733.16k | 0% $ 0 | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Interim CFO | less than a year | no data | no data | |
| Vice President of Operations | 2.1yrs | no data | no data | |
| VP of Corporate Development & Head of Business Development | less than a year | no data | no data | |
| VP and Head of Clinical Research & Development | less than a year | no data | no data |
2.1yrs
Average Tenure
65yo
Average Age
Experienced Management: DBTX's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 2.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.4yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 2.4yrs | no data | no data |
2.4yrs
Average Tenure
68yo
Average Age
Experienced Board: DBTX's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/06 12:32 |
| End of Day Share Price | 2023/09/22 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Decibel Therapeutics, Inc. is covered by 8 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Huidong Wang | Barclays |
| Matthew Luchini | BMO Capital Markets Equity Research |